# Novel G protein-based RSV vaccine

> **NIH NIH R44** · SCIOGEN, LLC · 2024 · $996,326

## Abstract

The overall objective of this Phase II SBIR proposal is to develop a novel G protein-based vaccine
for the prevention of disease associated with low respiratory tract infection (LRTI) by respiratory
syncytial virus (RSV). RSV is a leading cause of lower respiratory illness in infants and young
children worldwide. It also plays significant role in respiratory illness in the elderly. There is an
urgent need and compelling reasons to develop RSV vaccine. Past and current vaccine
development efforts are mainly focused on F protein-based recombinant vaccines and live
attenuated vaccines. Despite major efforts for several decades, an effective RSV vaccine remains
elusive. RSV G protein is responsible for viral attachment to host cells. However, only a single G-
based vaccine has been studied in humans to date. In the completed Phase I SBIR study, we
developed a novel RSV vaccine that has high sequence identity to type A and type B viruses. More
importantly, it provided complete protection against LRTI by type A and type RSV viruses in
animal models. The vaccine candidate did not cause vaccine enhanced disease. In this
submission, we propose to further develop this promising vaccine candidate through process and
analytical method development, evaluation of the vaccine candidate in maternal immunization
and aged cotton rat models, and conducting GLP toxicology study. The proposed work will
provide a critical foundation to move the G protein-based RSV vaccine candidate toward clinical
study.

## Key facts

- **NIH application ID:** 10832663
- **Project number:** 5R44AI149815-04
- **Recipient organization:** SCIOGEN, LLC
- **Principal Investigator:** SHENGQIANG LI
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $996,326
- **Award type:** 5
- **Project period:** 2020-08-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10832663

## Citation

> US National Institutes of Health, RePORTER application 10832663, Novel G protein-based RSV vaccine (5R44AI149815-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10832663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*